4896 Stock Overview
Engages in the research, development, manufacture, and sale of regenerative medicines and pharmaceutical products in Japan.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
K Pharma,Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥741.00 |
| 52 Week High | JP¥1,016.00 |
| 52 Week Low | JP¥531.00 |
| Beta | 0 |
| 11 Month Change | -5.36% |
| 3 Month Change | 4.66% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -21.75% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4896 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | 0.8% | 0.3% | 2.7% |
| 1Y | n/a | 13.7% | 10.1% |
Return vs Industry: Insufficient data to determine how 4896 performed against the JP Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 4896 performed against the JP Market.
Price Volatility
| 4896 volatility | |
|---|---|
| 4896 Average Weekly Movement | 10.6% |
| Pharmaceuticals Industry Average Movement | 5.1% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in JP Market | 10.4% |
| 10% least volatile stocks in JP Market | 3.5% |
Stable Share Price: 4896's share price has been volatile over the past 3 months.
Volatility Over Time: 4896's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | n/a | Hiroaki Fukushima | www.kpharma.co.jp |
K Pharma,Inc. engages in the research, development, manufacture, and sale of regenerative medicines and pharmaceutical products in Japan. It develops regenerative medicine products using disease-specific induced pluripotent stem (iPS) cell technology for spinal cord injuries and cerebral infarctions.
K Pharma,Inc. Fundamentals Summary
| 4896 fundamental statistics | |
|---|---|
| Market cap | JP¥8.60b |
| Earnings (TTM) | JP¥0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs 4896 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4896 income statement (TTM) | |
|---|---|
| Revenue | JP¥0 |
| Cost of Revenue | JP¥0 |
| Gross Profit | JP¥0 |
| Other Expenses | JP¥0 |
| Earnings | JP¥0 |
Last Reported Earnings
n/a
Next Earnings Date
Nov 14, 2024
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did 4896 perform over the long term?
See historical performance and comparison